DOSAGE AND ADMINISTRATION
The side effects of irbesartan are generally
rare and apparently independent of dose; those of hydrochlorothiazide are
a mixture of dose-dependent (primarily hypokalemia) and dose-independent phenomena
(e.g., pancreatitis), the former much more common than the latter. [See
antihypertensive effects are attained within 2 to 4 weeks after a change in
AVALIDE may be administered with or without food.
may be administered with other antihypertensive agents.
impairment. The usual regimens of therapy with AVALIDE may be followed
as long as the patient's creatinine clearance is >30 mL/min. In patients with
more severe renal impairment, loop diuretics are preferred to thiazides, so
AVALIDE is not recommended.
Hepatic impairment. No
dosage adjustment is necessary in patients with hepatic impairment.
In patients not controlled on monotherapy
with irbesartan or hydrochlorothiazide, the recommended doses of AVALIDE,
in order of increasing mean effect, are (irbesartan-hydrochlorothiazide) 150/12.5
mg, 300/12.5 mg, and 300/25 mg. The largest incremental effect will likely
be in the transition from monotherapy to 150/12.5 mg. [See
AVALIDE may be substituted for the titrated
The usual starting dose is AVALIDE 150/12.5
mg once daily. The dosage can be increased after 1 to 2 weeks of therapy to
a maximum of 300/25 mg once daily as needed to control blood pressure
AVALIDE is not recommended as initial therapy in patients with intravascular
volume depletion [see
Warnings and Precautions
DOSAGE FORMS AND STRENGTHS
150/12.5 mg and 300/12.5 mg film-coated tablets are peach, biconvex, and oval with a heart
debossed on one side and "2875" or "2876" on the reverse side, respectively.